<DOC>
	<DOCNO>NCT01281176</DOCNO>
	<brief_summary>This randomize pilot clinical trial study high-dose low-dose vorinostat combination carboplatin paclitaxel treat patient advance solid tumor . Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving different dos vorinostat together carboplatin paclitaxel may kill tumor cell .</brief_summary>
	<brief_title>High-Dose Low-Dose Vorinostat Combination With Carboplatin Paclitaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether high dose , short course vorinostat achieve high peak serum concentration standard dose . SECONDARY OBJECTIVES : I . To determine toxicity profile two different escalate intermittent dosing schedule vorinostat combine carboplatin area curve ( AUC ) 5 . II . To describe response rate patient advance solid tumor treat regimen . III . To develop pharmacodynamic marker vorinostat . IV . To determine toxicity profile escalate intermittent dosing schedule vorinostat 1200 mg combine paclitaxel 175 mg/m^2 describe response rate patient advance solid tumor treat regimen . OUTLINE : Patients randomize 1 4 treatment arm . ARM I : Patients receive high-dose vorinostat orally ( PO ) daily ( QD ) day 1-3 low-dose vorinostat PO QD day 8-10 ( course 1 ) . After 5 day , patient receive high-dose vorinostat PO QD day 1-3 carboplatin IV 30 minute day 3 subsequent course . ARM II : Patients receive high-dose vorinostat low-dose vorinostat arm I . After 5 day , patient receive lower-dose vorinostat PO QD day 1-3 carboplatin IV 30 minute day 3 subsequent course . ARM III : Patients receive low-dose vorinostat PO QD day 1-3 high-dose vorinostat PO QD day 8-10 ( course 0 ) . After 5 day , patient receive vorinostat carboplatin Arm I . ARM IV : Patients receive low-dose vorinostat high-dose vorinostat Arm III . After 5 day , patient receive vorinostat carboplatin Arm II . ARM V : Patients receive low-dose vorinostat PO QD day 1-3 mid-dose vorinostat PO QD day 8-10 ( course 0 ) . After 5 day , patient receive mid-dose vorinostat PO QD day 1-3 paclitaxel IV 3 hour day 3 . ARM VI : Patients receive mid-dose vorinostat PO QD day 1-3 low-dose vorinostat PO QD day 8-10 ( course 0 ) . After 5 day , patient receive vorinostat paclitaxel Arm V. In arm , course repeat every 21 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow 4 week .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must histologically confirm malignancy metastatic unresectable superior curative palliative measure know At least 4 week must pass since prior chemotherapy radiation therapy ; 6 week last regimen include BCNU mitomycin C Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great 3 month Leukocytes &gt; 3,000/mcL Absolute neutrophil count &gt; 1,500/mcL Platelets &gt; 100,000/mcL Total bilirubin &lt; institutional upper limit normal Potassium &lt; institutional upper limit normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 2.5 X institutional upper limit normal , &lt; 5 x ULN liver metastases present Creatinine within normal institutional limit OR creatinine clearance &gt; 60 mL/min/1.73 m^2 patient creatinine level institutional normal Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier ( except alopecia , lymphopenia , hyperglycemia , hypoalbuminemia elevate serum alkaline phosphatase ) ; toxicity resolve grade 1 less prior beginning treatment Patients may receive investigational agent Patients know brain metastasis untreated progressed definitive therapy exclude clinical trial ; patient treat brain metastasis , long receive steroid least 14 day , receive enzymeinducing antiepileptic drug , unstable neurologic symptom may enrol discretion joint decision principal investigator treat physician Prior current use valproic acid , histone deacetylase ( HDAC ) inhibitor History allergic reaction attribute compound similar chemical biologic composition paclitaxel , vorinostat carboplatin Inability swallow oral medication Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Women pregnant breastfeeding exclude study ; woman childbearing potential must negative pregnancy test receive vorinostat ; woman childbearing potential men must agree use adequate contraception duration study ; breastfeed discontinue mother treated vorinostat ; potential risk may also apply agent use study ; subject become pregnant think may pregnant take part study notify treat physician immediately Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible ; appropriate study undertake patient receive combination antiretroviral therapy indicate</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>